Published in N Engl J Med on October 08, 2016
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck | NCT04150900
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | NCT04376866
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 4.67
PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res (2017) 0.97
Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med (2017) 0.96
Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med (2017) 0.96
Temporally-Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res (2017) 0.95
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol (2017) 0.81
Approvals in 2016: the march of the checkpoint inhibitors. Nat Rev Clin Oncol (2017) 0.80
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev (2017) 0.78
PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst (2017) 0.77
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res (2017) 0.76
Checkpoint inhibition and melanoma: Considerations in treating the older adult. J Geriatr Oncol (2017) 0.76
European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Ther Adv Med Oncol (2016) 0.75
Nivolumab for recurrent squamous-cell carcinoma of the head and neck. Br Dent J (2016) 0.75
Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. Genes (Basel) (2017) 0.75
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology (2016) 0.75
Head and neck cancer in 2016: A watershed year for improvements in treatment? Nat Rev Clin Oncol (2016) 0.75
Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J (2017) 0.75
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer (2017) 0.75
Genomic sequencing and precision medicine in head and neck cancers. Eur J Surg Oncol (2016) 0.75
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. Oncoimmunology (2017) 0.75
Immunotherapy: More gain, less pain. Nat Rev Clin Oncol (2016) 0.75
Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract (2017) 0.75
PD-L1 expression in lung cancer. J Thorac Dis (2016) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget (2017) 0.75
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol (2017) 0.75
Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med (2017) 0.75
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics (2017) 0.75
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer (2017) 0.75
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS One (2017) 0.75
Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers (Basel) (2017) 0.75
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Des Devel Ther (2017) 0.75
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75
Single Fraction Stereotactic Radiosurgery for Retreatment of Skull Base Recurrent Head and Neck Malignancies. Cureus (2017) 0.75
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer (2017) 0.75
Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer. Otolaryngol Head Neck Surg (2017) 0.75
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab (2017) 0.75
mTOR co-targeting strategies for head and neck cancer therapy. Cancer Metastasis Rev (2017) 0.75
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol (2017) 0.75
Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. J Neurooncol (2017) 0.75
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight (2017) 0.75
Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics (Basel) (2017) 0.75
Cancer Immunotherapies: Are They as Effective in the Elderly? Drugs Aging (2017) 0.75
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature (2017) 0.75
Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma. Curr Oncol Rep (2017) 0.75
Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol (2017) 0.75
The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front Oncol (2017) 0.75
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab (2017) 0.75
Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions. Curr Psychiatry Rep (2017) 0.75
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. Oncoimmunology (2017) 0.75
Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol (2017) 0.75
Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. Oncotarget (2017) 0.75
New insights into the role of EMT in tumor immune escape. Mol Oncol (2017) 0.75
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology (2017) 0.75
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J (2017) 0.75
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag (2017) 0.75
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. Front Pharmacol (2017) 0.75
Epigenetics in oral squamous cell carcinoma. J Oral Maxillofac Pathol (2017) 0.75